111 related articles for article (PubMed ID: 38236544)
21. Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation.
van Elsas A; Hurwitz AA; Allison JP
J Exp Med; 1999 Aug; 190(3):355-66. PubMed ID: 10430624
[TBL] [Abstract][Full Text] [Related]
22. Enhancing CTL responses to melanoma cell vaccines in vivo: synergistic increases obtained using IFNgamma primed and IFNbeta treated B7-1+ B16-F10 melanoma cells.
Dezfouli S; Hatzinisiriou I; Ralph SJ
Immunol Cell Biol; 2003 Dec; 81(6):459-71. PubMed ID: 14636243
[TBL] [Abstract][Full Text] [Related]
23. Dendritic cell-based genetic immunization in mice with a recombinant adenovirus encoding murine TRP2 induces effective anti-melanoma immunity.
Tüting T; Steitz J; Brück J; Gambotto A; Steinbrink K; DeLeo AB; Robbins P; Knop J; Enk AH
J Gene Med; 1999; 1(6):400-6. PubMed ID: 10753065
[TBL] [Abstract][Full Text] [Related]
24. Reduced tumorigenicity of B16-F10 mouse melanoma cells transfected with mycobacterial antigen 85A.
Tarrant JP; Walsh MJ; Blanchard MC; Lee TD; Hoskin DW; Giacomantonio CA
Int J Oncol; 2004 Dec; 25(6):1693-9. PubMed ID: 15547707
[TBL] [Abstract][Full Text] [Related]
25. Vaccination with B16 melanoma cells expressing a secreted form of interleukin-1beta induces tumor growth inhibition and an enhanced immunity against the wild-type B16 tumor.
Björkdahl O; Dohlsten M; Sjögren HO
Cancer Gene Ther; 2000 Oct; 7(10):1365-74. PubMed ID: 11059695
[TBL] [Abstract][Full Text] [Related]
26. Eliciting T cell immunity against poorly immunogenic tumors by immunization with dendritic cell-tumor fusion vaccines.
Wang J; Saffold S; Cao X; Krauss J; Chen W
J Immunol; 1998 Nov; 161(10):5516-24. PubMed ID: 9820528
[TBL] [Abstract][Full Text] [Related]
27. Characterization of mouse melanoma cell lines by their mortal malignancy using an experimental metastatic model.
Nakamura K; Yoshikawa N; Yamaguchi Y; Kagota S; Shinozuka K; Kunitomo M
Life Sci; 2002 Jan; 70(7):791-8. PubMed ID: 11833741
[TBL] [Abstract][Full Text] [Related]
28. Adoptive transfer of immature dendritic cells with autologous or allogeneic tumor cells generates systemic antitumor immunity.
Melcher A; Todryk S; Bateman A; Chong H; Lemoine NR; Vile RG
Cancer Res; 1999 Jun; 59(12):2802-5. PubMed ID: 10383135
[TBL] [Abstract][Full Text] [Related]
29. Interleukin-23 and interleukin-27 exert quite different antitumor and vaccine effects on poorly immunogenic melanoma.
Oniki S; Nagai H; Horikawa T; Furukawa J; Belladonna ML; Yoshimoto T; Hara I; Nishigori C
Cancer Res; 2006 Jun; 66(12):6395-404. PubMed ID: 16778218
[TBL] [Abstract][Full Text] [Related]
30. CpG oligodeoxynucleotides augment antitumor efficacy of folate receptor α based DNA vaccine.
Qiu Z; Xing L; Zhang X; Qiang X; Xu Y; Zhang M; Zhou Z; Zhang J; Zhang F; Wang M
Oncol Rep; 2017 Jun; 37(6):3441-3448. PubMed ID: 28498413
[TBL] [Abstract][Full Text] [Related]
31. Protective immunization against melanoma by gp100 DNA-HVJ-liposome vaccine.
Zhou WZ; Kaneda Y; Huang S; Morishita R; Hoon D
Gene Ther; 1999 Oct; 6(10):1768-73. PubMed ID: 10516727
[TBL] [Abstract][Full Text] [Related]
32. Relevance of the tumor antigen in the validation of three vaccination strategies for melanoma.
Bellone M; Cantarella D; Castiglioni P; Crosti MC; Ronchetti A; Moro M; Garancini MP; Casorati G; Dellabona P
J Immunol; 2000 Sep; 165(5):2651-6. PubMed ID: 10946294
[TBL] [Abstract][Full Text] [Related]
33. Evaluation of antitumor immunity efficacy of epitope-based vaccine with B16 cell line coexpressing HLA-A2/H-2kb and CTL multiepitope in HLA transgenic mice.
Song S; Wang F; He X; He Y; Li D; Sun S
Vaccine; 2007 Jun; 25(25):4853-60. PubMed ID: 17418455
[TBL] [Abstract][Full Text] [Related]
34. Effective cancer immunotherapy based on combination of TLR agonists with stimulation of phagocytosis.
Caisová V; Uher O; Nedbalová P; Jochmanová I; Kvardová K; Masáková K; Krejčová G; Paďouková L; Chmelař J; Kopecký J; Ženka J
Int Immunopharmacol; 2018 Jun; 59():86-96. PubMed ID: 29635103
[TBL] [Abstract][Full Text] [Related]
35. Modulation of specific active immunization against murine melanoma using recombinant cytokines.
Stidham KR; Ricci WM; Vervaert C; Abdel-Wahab Z; Seigler HF; Darrow TL
Surg Oncol; 1996; 5(5-6):221-9. PubMed ID: 9129134
[TBL] [Abstract][Full Text] [Related]
36. Embryonic stem cell-derived dendritic cells expressing glypican-3, a recently identified oncofetal antigen, induce protective immunity against highly metastatic mouse melanoma, B16-F10.
Motomura Y; Senju S; Nakatsura T; Matsuyoshi H; Hirata S; Monji M; Komori H; Fukuma D; Baba H; Nishimura Y
Cancer Res; 2006 Feb; 66(4):2414-22. PubMed ID: 16489048
[TBL] [Abstract][Full Text] [Related]
37. Antitumor effects of anti-CD40/CpG immunotherapy combined with gemcitabine or 5-fluorouracil chemotherapy in the B16 melanoma model.
Qu X; Felder MA; Perez Horta Z; Sondel PM; Rakhmilevich AL
Int Immunopharmacol; 2013 Dec; 17(4):1141-7. PubMed ID: 24201083
[TBL] [Abstract][Full Text] [Related]
38. Sensitizing T-lymphocytes for adoptive immunotherapy by vaccination with wild-type or cytokine gene-transduced melanoma.
Lipshy KA; Kostuchenko PJ; Hamad GG; Bland CE; Barrett SK; Bear HD
Ann Surg Oncol; 1997 Jun; 4(4):334-41. PubMed ID: 9181234
[TBL] [Abstract][Full Text] [Related]
39. Syngeneic B16-F1 cells are more efficient than allogeneic Cloudman cells as antigen source in DC-based vaccination in the B16-F1 murine melanoma model.
Mac Keon S; Bentivegna S; Levy EM; Marks MS; Mantegazza AR; Wainstok R; Mordoh J
Vaccine; 2019 Aug; 37(35):4947-4955. PubMed ID: 31307876
[TBL] [Abstract][Full Text] [Related]
40. Factors Affecting Growth Kinetics and Spontaneous Metastasis in the B16F10 Syngeneic Murine Melanoma Model.
Fowlkes N; Clemons K; Rider PJ; Subramanian R; Wakamatsu N; Langohr I; Kousoulas KG
Comp Med; 2019 Feb; 69(1):48-54. PubMed ID: 30563585
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
